A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci, którzy świadomie zgodzą się na udział w badaniu.
- •Dorośli (powyżej 18 lat) z potwierdzoną przewlekłą białaczką szpikową.
- •Osoby, u których białaczka została niedawno zdiagnozowana lub które przyjmowały tylko jeden inny lek z grupy TKI.
- •Pacjenci, u których lekarz zdecydował o rozpoczęciu leczenia lekiem asciminib lub innym lekiem TKI w ramach standardowej opieki.
- •Osoby chętne do regularnych wizyt kontrolnych i wypełniania ankiet w trakcie badania.
✗ Disqualifies
- •Pacjenci, u których istnieją przeciwwskazania do stosowania leków na przewlekłą białaczkę szpikową.
- •Pacjenci, którzy przyjmują lub planują przyjmować lek asciminib lub inne leki TKI w sposób niezgodny z zatwierdzonym sposobem użycia.
- •Osoby aktualnie uczestniczące w innym badaniu klinicznym.
- •Pacjenci, którzy nie mogą lub nie chcą wyrazić świadomej zgody na udział w badaniu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Locations (41)
Novartis Investigative Site
Schwäbisch Hall, Germany
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Herrsching am Ammersee, Germany
Novartis Investigative Site
Kempten (Allgäu), Germany
Novartis Investigative Site
Munich, Germany
Novartis Investigative Site
Regensburg, Germany
Novartis Investigative Site
Bremerhaven, Germany
Novartis Investigative Site
Kassel, Germany
Novartis Investigative Site
Offenbach, Germany
Novartis Investigative Site
Rotenburg (Wümme), Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Cologne, Germany
Novartis Investigative Site
Solingen, Germany
Novartis Investigative Site
Zittau, Germany
Novartis Investigative Site
Merseburg, Germany
Novartis Investigative Site
Oldenburg in Holstein, Germany
Novartis Investigative Site
Saalfeld, Germany
Novartis Investigative Site
Bad Liebenwerda, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bremerhaven, Germany
Novartis Investigative Site
Buchholz Nordheide, Germany
Novartis Investigative Site
Cottbus, Germany
Novartis Investigative Site
Detmold, Germany
Novartis Investigative Site
Dorfen, Germany
Novartis Investigative Site
Dortmund, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Düren, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Hanover, Germany
Novartis Investigative Site
Hildesheim, Germany
Novartis Investigative Site
Mutlangen, Germany
Novartis Investigative Site
Naunhof, Germany
Novartis Investigative Site
Neuss, Germany
Novartis Investigative Site
Oldenburg, Germany
Novartis Investigative Site
Parchim, Germany
Novartis Investigative Site
Potsdam, Germany
Novartis Investigative Site
Potsdam, Germany
Novartis Investigative Site
Schorndorf, Germany
Novartis Investigative Site
Soest, Germany
Novartis Investigative Site
Stade, Germany
Novartis Investigative Site
Wetzlar, Germany
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.